鼻内地塞米松:控制COVID-19患者炎症与神经炎症的新临床试验
这是一项在墨西哥城五家医疗机构开展的开放标签、多中心、随机对照试验,计划纳入120例中重度COVID-19成年患者,按1:1随机接受低剂量鼻内或静脉地塞米松治疗10天,主要结局为鼻内较静脉地塞米松组NEWS-2评分出现统计学显著下降的临床改善,次要结局为住院期间死亡率降低。
要点
- 鼻内地塞米松可在中枢神经系统达到治疗浓度,而口服或静脉低剂量难以达到。
- 试验计划纳入120例中重度COVID-19成人,1:1随机分组,治疗10天。
- 主要结局为鼻内较静脉地塞米松组NEWS-2评分出现统计学显著下降的临床改善。
核心结论
- 该方案旨在提高标准地塞米松方案对中重度COVID-19患者的疗效,目前正在进行中。
研究设计与样本
- 已获批的开放标签、多中心、随机对照试验,比较低剂量鼻内与静脉地塞米松对中重度COVID-19成年患者的有效性。
- 方案在墨西哥城五家医疗机构开展,计划将120例患者按1:1比例随机分为静脉组与鼻内组。
- 两组均接受相应地塞米松方案治疗10天。
主要发现
- 主要结局为临床改善,定义为鼻内地塞米松组较静脉地塞米松组患者NEWS-2评分出现统计学显著下降。
- 次要结局为住院期间死亡率降低。
- 低剂量糖皮质激素口服或静脉给药可降低中重度COVID-19患者死亡率,但经这些途径给药不能在中枢神经系统达到治疗浓度。
- 鼻内地塞米松即使低剂量也可在中枢神经系统达到治疗剂量。
临床怎么用
- 该方案目前正在进行中,正在招募受试者,原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: By end December of 2021, COVID-19 has infected around 276 million individuals and caused over 5 million deaths worldwide. Infection results in dysregulated systemic inflammation, multi-organ dysfunction, and critical illness. Cells of the central nervous system are also affected, triggering an uncontrolled neuroinflammatory response. Low doses of glucocorticoids, administered orally or intravenously, reduce mortality among moderate and severe COVID-19 patients. However, low doses administered by these routes do not reach therapeutic levels in the CNS. In contrast, intranasally administered dexamethasone can result in therapeutic doses in the CNS even at low doses. METHODS: This is an approved open-label, multicenter, randomized controlled trial to compare the effectiveness of intranasal versus intravenous dexamethasone administered in low doses to moderate and severe COVID-19 adult patients. The protocol is conducted in five health institutions in Mexico City. A total of 120 patients will be randomized into two groups (intravenous vs. intranasal) at a 1:1 ratio. Both groups will be treated with the corresponding dexamethasone scheme for 10 days. The primary outcome of the study will be clinical improvement, defined as a statistically significant reduction in the NEWS-2 score of patients with intranasal versus intravenous dexamethasone administration. The secondary outcome will be the reduction in mortality during hospitalization. CONCLUSIONS: This protocol is currently in progress to improve the efficacy of the standard therapeutic dexamethasone regimen for moderate and severe COVID-19 patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT04513184 . Registered November 12, 2020. Approved by La Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) with identification number DI/20/407/04/36. People are currently being recruited.
引用
- Cárdenas G, Chávez-Canales M, Espinosa AM, et al. Intranasal dexamethasone: a new clinical trial for the control of inflammation and neuroinflammation in COVID-19 patients. Trials. 2022. PMID: 35164840. doi:10.1186/s13063-022-06075-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。